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Bioorthogonal labelling of biomolecules: new
functional handles and ligation methodsQ1
Marjoke F. Debets, Jan C. M. van Hest and Floris P. J. T. RutjesQ2 *
This review provides a literature overview of bioorthogonal ligation methods for protein modiﬁcation,
which have largely evolved over the last 15 years. Since 1990, various new reactions have been developed
that do not involve naturally occurring functional handles. Especially the development of such so-called
bioorthogonal ligations has signiﬁcantly contributed to our ability to selectively modify biomolecules not
only in the test tube, but also in living systems.
1. Introduction
Bioconjugation is the process of linking two or more mole-
cules, of which at least one is a biomolecule. In this way, the
properties of individual components are combined.1 Clearly,
there are numerous examples of reactions ligating two or more
molecules; however, biomolecule labelling poses important
limitations on the reaction conditions that can be applied
(solvent, concentration, temperature) and on the available
reactive groups.
In general, biological systems flourish best in an aqueous
environment meaning that reagents for bioconjugation should
be stable in aqueous systems, and reactions need to proceed in
water. In addition, biomolecules, and even more so their reac-
tive groups, are present only in low concentrations. Therefore,
reaction rates need to be high in order to obtain significant
modifications within a convenient time span.
Many methods are known for modifying functional groups
which are naturally present in biological systems,2,3 but logi-
cally this poses significant challenges for achieving selectivity
and in particular for in vivo applications. This realisation has
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led to the fast development of bioorthogonal reactions which,
apart from the previously mentioned requirements for bio-
conjugation, need to be selective for their target, and should
not give cross-reactivity with any of the naturally occurring
functional groups.
Besides expanding the scope of biomolecule modification,
bioorthogonal ligation allows for the selective and controlled
introduction of labels, not only in single proteins, but also on
cell-surfaces, in living cells and even in live animals. These fea-
tures open up new opportunities for studying biological pro-
cesses that do not exist when relying on, for example, more
conventional lysine or cysteine labelling.
Although the complete genome of many organisms has
been elucidated, many biological processes like post-transla-
tional modifications, protein–protein interactions, and protein
translocation are not yet fully understood. With new bioortho-
gonal ligation reactions it has been possible to e.g. study
protein formation during embryogenesis,4 image tumours,5
and track glycan formation and translocation.6
In the last decade, research on bioconjugation has grown at
an incredible pace, and thousands of papers have been pub-
lished on new ligation methods or applications thereof. This
review oﬀers an overview of the diﬀerent bioorthogonal lig-
ation strategies available for protein modification. We will
thereby focus on azide-related ligation strategies, and more
specifically on the Strain-Promoted Azide Alkyne Cycloaddition
(SPAAC), since this is one of the most actively pursued ligation
methods during the last decade. Furthermore, since the inter-
est in dual labelling has significantly increased recently, we
will devote the last section of this review to describing the
mutual orthogonality of those bioorthogonal reactions.
2. Bioorthogonal reactions
Since the first modification of a biological system using an
unnatural functional group in 1996,7 various new bioorthogo-
nal reactions have been published.8–11 Handles which have
been shown to be bioorthogonal and applicable in biological
system modification include aldehydes, azides, nitrones,
nitrile oxides, diazo compounds, tetrazines, tetrazoles, quadro-
cyclanes, alkenes, and iodobenzenes. All bioorthogonal reac-
tions used in bioconjugations described in this review are
summarized in Table 1.
2.1 Ligations with ketones and aldehydes
The first non-natural functional handle to be used for protein
modification was the carbonyl group present in aldehydes and
ketones. Although this moiety can react with amines forming
imines, in physiological media the carbonyl lies in the
favoured site of the equilibrium. On the other hand, ketones
and aldehydes do form stable conjugation products with
alkoxyamines (Table 1, entry 1) and hydrazines (Table 1,
entry 2), forming oxime ethers and hydrazones, respectively.12
These reactions have been used for the labelling of
proteins,7 including in living cells,13 virus particles,14 and cell
surfaces.15
Recently, Bertozzi et al. showed that aldehyde-containing
proteins can be modified with a Pictet–Spengler type reaction
(Table 1, entry 3). This reaction showed good pH-dependent
rate constants varying between 10.5 M−1 s−1 (pH 4.5) and 0.26
M−1 s−1 (pH 7). In addition, they compared the stability
towards hydrolysis of the formed oxacarboline-linked product
to the corresponding oxime-linked product. They found that
the oxime-linked product is almost completely hydrolyzed
within a week, while the oxacarboline-linkage is stable towards
hydrolysis over this period.16
2.2 Ligations with azides
Currently, organic azides are the most commonly used
reagents in the modification of biological systems. Their popu-
larity can be explained by the inertness and small size of the
azide moiety, which therefore generally has only minimal
eﬀect on the structure of the substrate in which it is intro-
duced.17 They are also readily introduced in biomolecules via
e.g. diazo-transfer onto amines,18 non-natural amino acid
incorporation,19 or expressed protein ligation.20–22 Finally and
most importantly, azides have a unique reactivity.
Reaction of azides in a Staudinger reduction and the
Huisgen 1,3-dipolar cycloaddition were already well estab-
lished in the previous century; however, these reactions either
do not lead to bond formation between the two reaction part-
ners, or require too harsh conditions for protein labelling.
2.2.1 Staudinger ligation. In 2000, Bertozzi et al. develo-
ped a Staudinger ligation reaction (Table 1, entry 5). This is a
ligation between an azide and a triphenylphosphine derivative
(PHOS, Table 2, entry 1) and is a modification of the long-
known Staudinger reduction which was now applied for the
formation of an amide bond via rearrangement of the aza-ylide
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Table 1 Summary of bioorthogonal reactions used in the modiﬁcation of biomolecules
Entry Functional handle Reaction partner Product Catalyst
1 None
2 None
3 None
4 Cu(I) or Ru(II)a
5 None
6 None
7b None
8 Cu(I) or Ru(II)c
9b None
10b None
11b None
12b None
13b None
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intermediate.23 Key to the Staudinger ligation is the intramole-
cular trapping of a nucleophilic aza-ylide by an electrophilic
ester, leading to a covalent amide bond via a putative penta-
coordinate phosphine intermediate (Scheme 1).24 This reac-
tion proceeds with a rate constant of 2.4 × 10−3 M−1 s−1. An
alternative was developed by Raines and co-workers, who
combined the Staudinger reduction with native chemical lig-
ation (NCL) (Table 1, entry 6).25 The power of the Staudinger
ligation for in vitro applications was elegantly demonstrated in
the cell-surface labelling of Jurkat and HeLa cells.23 The Stau-
dinger ligation has also been applied for cell surface remodel-
ling,26 live-cell imaging,27 and the visualisation of O-linked
Table 1 (Contd.)
Entry Functional handle Reaction partner Product Catalyst
14b None
15b None
16b None
17b None
18b None
19b None
20b UV-light
21b UV-light
22b UV-light
23b None
24 Grubbs’ catalyst
25 Pd(OAc)2(ligand)2
26 Pd(OAc)2(ligand)2
a Cu(I) catalysis yields the 1,4-isomer, and Ru(II) yields the 1,5-isomer. b Both regioisomers are obtained, although only one is shown in the table.
c Catalyst is only required when regioselective control is desired, Cu(I) yielding the 1,4-isomer and Ru(II) yielding the 1,5-isomer.
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glycosylation in live mice.28 Mice were labelled with azides via
the metabolic incorporation of azide-functionalised sugars.
After 8 days the mice were sacrificed and diﬀerent organs were
labelled with PHOS-FLAG followed by FITC-α-FLAG29 followed
by fluorescence imaging or the organs were harvested and
homogenised followed by treatment with PHOS-FLAG and ana-
lysis by Western Blot using horseradish peroxidase-α-FLAG.
Labelling was observed in diﬀerent organs, e.g. liver, kidney,
Table 2 Overview of azide-reactive probes, synthesis, rate constant and lipophilicity
Entry Azidophile Name Synth. steps Yield [%] ka [× 10−3 M−1 s−1] Solvent log Pb,c Ref.
1 PHOS 2 50 2.1 CD3CN 4.74 23
2 OCT 1 4 52 2.4 CD3CN 3.21 33
3 OCT 2 5 36 1.3 CD3CN 1.65 52
4 OCT 3 4 12 1.2 CD3CN 3.77 52
5 MOFO 5 15 4.3 CD3CN 3.76 52
6 DIFO 1 10 1.2 76 CD3CN 1.28 6
7 DIFO 2 8 27 42 CD3CN 4.14 53
8 DIFO 3 10 21 52 CD3CN 1.71 53
9 BCN 4 15/35c 110/140c CD3CN–D2O (3 : 1) 2.01 50
10 TMTH 6 0.8 4000 CD3CN 4.00 61
11 DIMAC 11 5 3 CD3CN 0.66 62
12 DIBO 1 5 10 57 CH3OH 4.40 63
13 DIBO 2 5 9 76.3 CH3OH 5.96 64
14 S-DIBO 6 18 112 CH3OH 0.59 65
15 DIBAC 9 41 310 CD3OD 3.51 67
16 BARAC 6 18 960 CD3CN 4.20 51
17 COMBO 6 11 240 CD3CN 2.19 74
18 OXA 1 2 59 0.85 CD3OD 0.27 80
19 OXA 2 2 58 0.41 CD3OD 0.78 83
a 2nd order reaction rate constant determined with benzyl azide as the model, unless otherwise indicated. bCalculated by BioByte (embedded in
ChemBioDraw 12.0) for the N-methylamide derivative of carboxylic acids and the N-methyl carbamate derivative of alcohols. c Exo-BCN/endo-BCN.
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heart, and serum. In addition, it was observed that when mice
were treated with peracetylated N-azidoacetylmannosamine
(Ac4ManNAz) diﬀerent glycans were labelled than when mice
were treated with peracetylated N-azidoacetylgalactosamine
(GalNAz). Later, it was shown that the Staudinger ligation can
also be used to label the azido-sugars in live mice.30 The Stau-
dinger ligation has also been used for protein and DNA modi-
fication, and has been applied in activity-based profiling.31 A
nice addition to the Staudinger ligation potential was made by
the development of a fluorogenic Staudinger probe, which
turns fluorescent upon ligation.27
The alternative Staudinger ligation developed by Raines
et al. requires a thioester as one of the ligating components,
which significantly reduces the scope of the reaction. Nonethe-
less, this ligation found application in the attachment of pro-
teins to a surface.32
Although the Staudinger ligation developed by Bertozzi
et al. has proven to be a selective and eﬃcient reaction, some
specific disadvantages can be recognised. First of all, because
phosphines are prone to oxidation by air, shelf-stability is
limited and oxidation may take place before ligation. Secondly,
the Staudinger ligation is relatively slow.24 Unfortunately,
improvement of the kinetics and water solubility proved
troublesome.33
2.2.2 Cu-catalysed 1,3-dipolar cycloaddition (CuAAC). The
discovery by Meldal34 and Sharpless35,36 that the 1,3-dipolar
cycloaddition of azides and acetylenes can be catalysed by
sources of copper(I) (Table 1, entry 4) has been of tremendous
value for organic synthesis,37 library synthesis of pharmaco-
phores,38 and bioorthogonal ligations. Over the last decade,
the CuAAC has been used in protein modification,39 DNA and
RNA modification,40 and glycan imaging.41 Although cyclo-
addition has found wide application in chemical biology
research, the required Cu(I)-catalyst has appeared to be toxic to
living systems, causing cell death, preventing cell division, and
killing zebrafish embryos.2 Cu-ions are toxic mainly because
they catalyse the production of reactive oxygen species from
atmospheric oxygen.42 It was recently shown that the addition
of certain ligands can not only increase reaction speed but
also significantly reduce the toxic eﬀects.43 Finn et al. showed
that when THPTA (Fig. 1) was used as a ligand in a 5 : 1 ratio
compared to Cu(I) all cell types tested survived and showed
consistent labelling using CuAAC. In this manner, they
labelled live cells and showed that labelling did not aﬀect
glycan traﬃcking.42 Wu showed that a further improved ligand
(BTTES, Fig. 1) even made CuAAC applicable for live zebrafish
labelling. Alkyne functionalities were introduced by incorporat-
ing alkyne-containing sugars and zebrafish were subsequently
fluorescently labelled by the addition of an azide-dye and
BTTES–Cu(I) complex.44
Although toxicity issues of Cu(I) can be solved by the
addition of ligands, bioorthogonal labelling without the need
of a metal catalyst is more straightforward. Especially in larger
animals, colocalisation of the catalyst, azide, and alkyne
reagents is probably hard to achieve. In addition, some appli-
cations, e.g. ligation of metal-chelators or modification of
metal-binding enzymes, require metal-free conditions.
2.2.3 Strain-promoted azide alkyne cycloaddition (SPAAC).
Already in 1953, Blomquist and Liu published the first syn-
thesis of cyclooctyne and its suspected ring-strain, which
became apparent from the reported explosive reaction of
cyclooctyne and phenyl azide.45 The structural identity of
the resulting liquid was later corroborated as the product of
a 1,3-dipolar cycloaddition.46 Ever since, many diﬀerent
cycloalkynes have been reported. It was noted that a cyclo-
octyne is the smallest cycloalkyne which can be isolated.
However, when bigger atoms are added (e.g. Si or S), also cyclo-
heptynes can be isolated, especially when stabilised by the
addition of methyl-groups adjacent to the alkyne.47
In spite of all this work, mainly performed in the 1960s and
1970s, it was not until 2004 that Bertozzi and co-workers
realised the potential of these strained alkynes in the strain-
promoted azide alkyne cycloaddition (SPAAC, Table 1, entry
7).33 Ever since Bertozzi et al. demonstrated that cyclooctynes
react spontaneously with azides in SPAAC and that this reac-
tion could be used for cell-surface labelling, many new ring-
strained systems have been published.48,49 An overview of the
published strained azide reactants is given in Table 2.
The following section will describe the development of
the diﬀerent azide-reactive strained alkynes. Considering
(dibenzo)cyclooctynes, it must be noted that, although much
progress has been made in the development of more reactive
cyclooctynes, these improvements often came with a price.
Some of the faster cyclooctynes are not shelf-stable (BCN)50 or
Scheme 1 Staudinger ligation of a 2-(diphenylphosphoryl)benzoic ester with an alkyl azide.
Fig. 1 Cu(I)-ligands used in CuAAC for in vitro and in vivo applications.
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show significant cross-reactivity with thiols (BARAC51 and
DIFO).6 Also, most cyclooctynes are highly hydrophobic, and
need to be prepared via lengthy and/or low yielding synthetic
routes (Table 2). In fact, for many of these systems hydrophili-
city and reaction kinetics are inversely related, as is shown in
Fig. 3 where a plot is shown of all rate constants versus lipophi-
licity. Lastly, the crucial step in all cyclooctyne syntheses is the
last, alkyne-forming step, which is the most troublesome step.
This renders cyclooctyne synthesis a cumbersome and time-
consuming process.
2.2.3.1 Cyclooctynes. The first cyclooctynes developed were
OCT 1 (Table 2, entry 2) and OCT 2 (Table 2, entry 3) which
could be synthesised in four steps (52 and 10% yield, respect-
ively). Compared to the Staudinger ligation (Table 2, entry 1)
both probes were significantly less prone to oxidation, but
nevertheless not fully shelf-stable since prolonged storage of
OCT 1 and OCT 2 at −20 °C led to decomposition. The develo-
ped 3-alkoxycyclooctynes showed rate constants for the cyclo-
addition with benzyl azide comparable to those of the
Staudinger ligation (k = 2.4 × 10−3 M−1 s−1 for OCT 1 and k =
1.3 × 10−3 M−1 s−1 for OCT 2).33
To increase the stability of the 3-alkoxycyclooctyne deriva-
tives, an alternative was developed with the alkyl-linked
cyclooctyne conjugate OCT 3 (Table 2, entry 4).52 Indeed, the
latter was found to be more stable than OCT 1; however, the
reactivity of OCT 3 towards azides (k = 1.2 × 10−3 M−1 s−1) was
also two-fold lower.
Since the alkyl-linked cyclooctyne was found to be more
stable but less reactive than earlier cyclooctynes, a fluoride
substituent was introduced adjacent to the acetylene.52 It was
assumed that lowering of the LUMO of the acetylene by a
neighbouring electron-withdrawing group would increase the
reactivity towards azides. Indeed MOFO (Table 2, entry 5) (syn-
thesised in 15% yield over five steps) displayed a four-fold
enhanced reactivity towards benzyl azide (k = 4.3 × 10−3 M−1
s−1).52 Surprisingly, when this probe was applied in cell-
surface labelling and compared to OCT and Phos, the Staudin-
ger ligation still outperformed the cyclooctynes, despite the
better kinetics of MOFO. Possibly, the Staudinger ligation is
more eﬃcient with azides bearing electron-withdrawing or res-
onance-stabilising groups.52
The fact that monofluorination of the cyclooctyne system
enhanced the reactivity was a stimulus for Bertozzi et al. to
synthesise a difluorinated cyclooctyne (DIFO 1, Table 2, entry
6).6 Although synthesis was troublesome and DIFO 1 was
obtained in poor overall yield (1.2% over ten steps), this was
fully compensated for by the observed rate constant. DIFO 1
reacted with benzyl azide with a rate constant of 7.6 × 10−2
M−1 s−1, about 17-fold faster than the fastest previously
reported Cu-free ligation. The high reactivity of DIFO 1 was
also reflected in staining of Jurkat cells bearing SiaNAz with
biotinylated DIFO 1, which proceeded with a 20-fold higher
eﬃciency than with other cyclooctynes.
The great potential of DIFO 1 validated an alternative syn-
thetic route. To avoid the cumbersome elimination step to the
alkyne, Bertozzi et al. developed a synthesis with the ether
linkage replaced by an alkyl linker.53 Notably, elimination of
the triflate now proceeded with excellent yield, and the total
synthesis of DIFO 2 (Table 2, entry 7) was completed in eight
steps with an overall yield of 27%.53 Another DIFO-derivative,
lacking the phenyl ring in the linker (DIFO 3, Table 2, entry 8),
was also prepared (ten steps, 21% overall yield) to reduce non-
specific protein and cell binding as a result of the lipophilic
character of DIFO 2.
Kinetic experiments of DIFOs 2 and 3, termed 2nd gene-
ration DIFOs, with benzyl azide revealed rate constants of
4.2 × 10−2 M−1 s−1 for DIFO 2 and 5.2 × 10−2 M−1 s−1 for DIFO 3,
slightly lower but similar to 1st generation DIFO. The relative
rate constants were also reflected in the labelling of Jurkat
cells that showed a 3-fold higher fluorescence for DIFO 1 than
for DIFOs 2 and 3. As expected, with respect to DIFO 2, slightly
less background labelling was observed for DIFO 3, lacking the
hydrophobic phenyl group, in flow cytometry experiments. It
must however be noted that DIFO was found to be less stable
in serum compared to dibenzocyclooctynes, possibly due to its
susceptibility towards Michael addition.54,55
A diﬀerent way to attain a rate increase for cyclooctynes was
published by van Delft et al.50 They envisioned that installing a
cyclopropane ring in the cyclooctyne opposite to the triple
bond would result in additional ring strain and thereby
increased kinetics. BCN (Table 2, entry 9) could be prepared in
four steps, yielding both the exo- (15% yield) and endo-isomers
(35% yield). The cyclopropane ring indeed increased ring-
strain and thereby the rate constant. With rate constants of
0.11 M−1 s−1 for exo-BCN and 0.14 M−1 s−1 for endo-BCN, BCN
is the fastest cyclooctyne known. Nonetheless, BCN was found
to have limited shelf-stability, even at lower temperatures.50,56
Another alternative for increasing ring-strain is by decreas-
ing the ring size. Benzyne-rings have been prepared and used
in, among others, 1,3-dipolar cycloadditions. However,
benzyne needs to be made in situ and cannot be isolated.57–60
On the other hand, Krebs had already summarised in 1983
that some heteroatom-containing cycloheptynes can be pre-
pared and isolated.47 Only recently, Bertozzi et al. showed the
synthesis of a thiacycloheptyne (TMTH, Table 2, entry 10) in
0.8% yield over six steps.61 The rate constant of the reaction of
TMTH with benzyl azide was 4 M−1 s−1. For comparison pur-
poses, also thiacyclooctyne was prepared, showing a rate con-
stant of 3.2 × 10−4, which is one order of magnitude lower
than the rate observed for OCT 1. The eﬀect of decreasing the
size of the alkyne-containing ring with one atom was thus
shown to be at least four orders of magnitude, although it is
likely that the rate constant of thiacycloheptynes would even
be higher without the adjacent methyl groups. Unfortunately,
TMTH could not be equipped with a label; protein modifi-
cation was however confirmed by mass spectrometry.
The cyclooctynes, as described above, all consist of only
carbon atoms in the ring and have, without exception, negli-
gible water solubility. Furthermore, background labelling was
observed in biological experiments due to hydrophobic inter-
actions with cell membranes and non-specific binding to
serum proteins cannot be excluded. Therefore, Bertozzi et al.
Organic & Biomolecular Chemistry Perspective
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set out to develop a more hydrophilic cyclooctyne by introduc-
tion of a nitrogen to break the hydrophobic character of the
ring.62 In addition, two methoxy groups were introduced to
enhance polarity and water solubility. DIMAC (Table 2, entry
11) showed a kinetic constant of 3.0 × 10−3 M−1 s−1, slightly
faster than parent OCT 1, but significantly lower than DIFO
1. Nonetheless, DIMAC was found to be suitable for detection
of metabolically incorporated ManNAz in Jurkat cells. As
expected, background labelling was significantly lower than
that for cyclooctyne OCT 2.
2.2.3.2 Dibenzocyclooctynes. Another interesting class of
highly strained alkynes are the (di)benzocyclooctynes. Boons
et al. envisioned that the introduction of fused aryl rings into
the cyclooctyne system would enhance reaction kinetics by
increased ring-strain and conjugation.63 To this end, they
designed DIBO 1 (Table 2, entry 12), and prepared it in five
steps with an overall yield of 10%. In kinetic experiments,
cycloaddition of DIBO with benzyl azide proceeded with a rate
constant of k = 5.67 × 10−2 in methanol, about the same as
that for DIFO 1.
In a follow-up paper by Popik et al., a photo-triggerable
cyclopropenone system was developed that formed the alkyne
functionality upon UV-irradiation at 350 m.64 Conveniently,
the major product was isolated with one butyl group hydro-
lysed, thereby providing a handle for subsequent
functionalisation.
While the cyclopropenone showed no reaction with azides,
irradiation at 350 m resulted in the rapid formation (1 in) of a
cycloalkyne (DIBO 2, Table 2, entry 13) that reacted with
benzyl azide with a rate constant of 7.63 × 10−2 M−1 s−1, as
determined with a newly developed UV-based procedure.
In addition, recently a disulfated DIBO (s-DIBO, Table 2,
entry 14) analogue was prepared, showing impressive water
solubility compared to DIBO.65 In addition Boons et al. found
that s-DIBO did not cross the cell membrane whereas DIBO
did. s-DIBO could thus be used for selective labelling of mem-
brane glycoproteins.
Disadvantages of all the above described dibenzocyclo-
octynes are that, again, all ring-members are carbon atoms,
and labelling of the hydroxyl via an ester- or carbamate linkage
gave rise to problems with hydrolysis when labelling lipases.66
Therefore, van Delft et al. envisioned that introduction of a
nitrogen atom into the octyne-ring would break the hydro-
phobic character of the ring and allow for more stable amide-
bond functionalization. This resulted in the preparation
of dibenzoazacyclooctyne (DIBAC, Table 2, entry 15) in
41% yield over nine steps.67 Kinetic experiments with benzyl
azide showed an over 4-fold higher rate constant compared
to DIBO 1 in reaction with benzyl azide in CD3OD (k =
0.31 M−1 s−1).
The rate of dibenzoazacyclooctynes could be further
increased by the introduction of an amide bond into the eight-
membered ring. This was pursued by Bertozzi et al. who pre-
pared BARAC (Table 2, entry 16) in six steps and an overall
yield of 18%.51 BARAC reacted with benzyl azide with a rate
constant of 0.96 M−1 s−1.
However, BARAC is susceptible to Michael addition with
thiols, though at a much lower rate than its cycloaddition with
azides. Modelling studies by Houk et al. showed that the rate
increase was caused by increased bond distortion of the alkyne
bonds.68
The route towards BARAC was proven to be a highly versa-
tile one, as several analogues with substituents on the benzene
rings could be prepared by following the same synthetic
pathway.68 In this research, it was shown that electron-with-
drawing and electron-donating groups on the aromatic rings
have a positive eﬀect on the rate constant. As expected, the
electron-withdrawing groups showed a larger eﬀect on the
reaction speed than electron-donating groups. Remarkably,
ortho-substitution with respect to the alkyne resulted in an
impressive drop in cycloaddition reactivity.
A non-functionalisable dibenzocyclooctadiyne has long
since been known and used in organic synthesis, for e.g. the
preparation of extended aromatic systems, cyclophane syn-
thesis and metal-complex formation.69–71 This compound can
react with azides twice, which theoretically would eliminate
the need to introduce a functional handle as one of the two
azides could be a functional handle. However, it was observed
that the triazole-containing compound formed in the first
cycloaddition is more reactive to a second cycloaddition to
such an extent that always the bistriazole is formed. Neverthe-
less, Hosoya et al. showed that when used for protein modifi-
cation the sterics of the protein avoid dimerization of the
protein, leaving one highly strained alkyne intact.72 This
alkyne can subsequently be used for protein labelling in a
second strain-promoted reaction.
Alternatively, some monobenzocyclooctynes have been pre-
pared to decrease the hydrophobicity of the probes, but main-
tain the reactivity. Bertozzi et al. prepared MOBO and a
difluorinated variant (DIFBO). MOBO showed a rate constant
of 9.5 × 10−3 M−1 s−1, about one order of magnitude slower
than DIBO. On the other hand, as expected, introduction of
two fluorides resulted in a 20-fold rate increase (0.22 M−1 s−1).
However, DIFBO could not be isolated unless stabilised by the
addition of β-cyclodextrin.73 Recently, Kele et al. synthesised
COMBO (Table 2, entry 17), which has the benzene ring oppo-
site to the alkyne. COMBO has a rate constant of 0.23 M−1 s−1,
almost identical to DIFBO and about 2-fold higher than the
closely resembling BCN.74
2.2.3.3 Fluorogenic dibenzocyclooctynes. A separate class of
dibenzocyclooctynes is formed by the fluorogenic probes.
These molecules are not fluorescent in the alkyne state, but
become fluorescent upon reaction with azides. This has
several advantages over non-fluorogenic cyclooctynes. First of
all, no fluorescent label needs to be introduced, thereby
excluding the need of introducing a functionalisable handle
which may compromise alkyne formation. In addition, a
specific labelling, which is often a problem in biological exper-
iments, is eliminated as no triazole formation is required for
fluorescence to occur.
Fluorogenic azides, turning fluorescent upon cycloaddition,
have been published. The first was based on coumarin, but
Perspective Organic & Biomolecular Chemistry
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such dyes are relatively unstable and the emission wavelength
is not suitable for biological purposes.75,76 Recently, Bertozzi
et al. published a fluorogenic azide based on fluorescein,
which proved suitable for cell-surface labelling.77 In addition
to fluorogenic azides, a fluorogenic coumarin-based alkyne
was reported.75 Inspired by this alkyne, Bertozzi et al. develo-
ped a fluorogenic cyclooctyne based on BARAC, coumBARAC
(Fig. 2). This compound was prepared in 2% yield over six
steps.78 The dibenzocyclooctyne had, however, a similar exci-
tation pattern to other coumarins and displayed only a mode-
rate quantum yield. Another fluorogenic cyclooctyne (Fl-DIBO,
Fig. 2) was published by Boons et al.79 While the synthesis pro-
ceeded more smoothly (35% yield over five steps), the exci-
tation pattern was similar to coumBARAC, still not overlapping
with commonly used excitation wavelengths in biology
research.
2.2.3.4 Oxanorbornadienes. The concept of cycloaddition
of azides to strained bonds was also investigated for oxanor-
bornadienes by Rutjes et al.80 It was envisioned that these oxa-
norbornadienes, apart from thiol-addition as described
above,81 could undergo cycloaddition with azides. Ju et al.
already discovered that the spontaneous reaction of electron-
deficient alkynes with azides proceeded in good yields under
aqueous conditions.82 Formation of an oxanorbornadiene
from one of these electron-deficient alkynes yielded OXA
1. Treatment of OXA 1 (Table 2, entry 18) with an alkyl azide
gave a triazoline intermediate that underwent retro-Diels–Alder
reaction, leading to the triazole products and furan
(Scheme 2). It was found that OXA 1 is partly susceptible to
cycloaddition of the azide on the other double bond
(Scheme 2). Introduction of a methyl-substituent (OXA 2,
Table 2, entry 19), by initial reaction with 3-methylfuran, eﬀec-
tively eliminated the latter disadvantage.83 While the rate con-
stant of cycloaddition of OXA 1 with azide is relatively low
(k = 8.5 × 10−4 M−1 s−1), and even slightly lower for OXA 2 (k =
4.2 × 10−4 M−1 s−1), advantages of the oxanorbornadiene
system are the easy preparation and high water solubility. The
high hydrophilicity of OXA 1 and OXA 2 is clearly shown in
Fig. 3. This figure shows the relation between the rate constant
and lipophilicity of all azide-reactive probes, summarised
in Table 2. It also shows that in general the more reactive
a probe is, the more hydrophobic it will become. An outstand-
ing example is s-DIBO, which shows a similar reactivity to
BCN, DIFO and DIBO, but has a hydrophilicity compared to
DIMAC and OXA, due to the introduced sulfate-groups.
2.2.4 Applications of SPAAC. The reaction between azides
and highly strained probes has found wide application in
many research areas. Probably, the numerous ways for azide
introduction, combined with its stability and small size,
render the azide a highly desirable handle for modification. In
addition, due to the high research interest in cyclooctyne
development, many fast cyclooctynes have been developed,
allowing for fast labelling at low concentrations.
In the last decade numerous applications of SPAAC have
been published;84 describing all these examples would be too
elaborate for this review. In short, SPAAC has been used for
Scheme 2 Cycloaddition of oxanorbornadiene with azide, followed by a retro-Diels–Alder reaction.
Fig. 3 Reactivity versus lipophilicity of functionalized cyclooctynes, based on
Table 2.
Fig. 2 Fluorogenic cyclooctynes.
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live cell labelling, protein labelling, lipid labelling, monitoring
of non-natural amino acid incorporation, studying protein
interactions, surface modification, preparation of radio-
labelled substrates, polymer conjugation, proteomics, and
in vivo imaging.9,17,49,85
An especially appealing field of applications is of course the
in vivo applications of SPAAC, as these allow for direct visual-
isation of biological processes.
Bertozzi et al. showed that SPAAC could be used for the
tracking of glycan synthesis in zebrafish.4 Growing zebrafish in
the presence of GalNAz, to incorporate azide handles in glyco-
proteins, followed by labelling resulted in observed glycan for-
mation 24 hours post fertilisation. Especially between 60 and
72 hours after fertilisation a large increase in fluorescence was
observed in the jaw region, pectoral fins, and olfactory organs.
Further investigation was performed by labelling with diﬀerent
dyes at separate time points, thereby increasingly elucidating
the synthesis of glycans in live zebrafish. Later it was shown
that glycans could be imaged as soon as 7 hours post fertilisa-
tion, albeit that the azido-sugar needed to be micro-injected.86
It was also shown that SPAAC can be used for the labelling
of mice splenocytes. To this end, mice were fed with azido-
sugars for 7 days, whereupon diﬀerent FLAG-labelled cyclo-
octynes were administered. After three hours, the mice were
sacrificed and diﬀerent splenocytes were analysed for label-
ling. Using diﬀerent azide-reactive probes (PHOS, DIMAC, and
DIFO) labelling of proteins in liver, heart and intestines was
possible. Notably, when OCT 2 was used no protein labelling
was observed, likely due to the low kinetics and limited
absorption from the peritoneal cavity (where the cyclooctynes
were injected) into the bloodstream.30
Recently, SPAAC was also used in mice to attach a trans-
cyclooctene (TCO) to GalNAz-containing tumour cells. Sub-
sequently the TCO was used for fluorescent labelling using an
inverse-electron Diels–Alder reaction (described in Section
2.4).87
2.3 Ligations with other 1,3-dipoles
Compared to azides, nitrile oxides and nitrones are stronger
1,3-dipoles, making them faster partners in cycloadditions.
Unfortunately, this also renders them less stable and therefore
more troublesome in biochemical applications. For example,
nitrile-oxides require in situ formation just before use88 and
nitrones can, due to their instability, not be introduced to cell
surfaces.89 An advantage of using nitrile oxides is that,
because of their increased reactivity, they react with simple
terminal alkynes without the need of a catalyst (Table 1, entry
8). This feature has mainly been applied by Heaney et al. for
the modification of ribonucleosides.90 In addition, Ravoo and
co-workers showed that this reaction can be used for surface
modification.91 Carell et al. demonstrated that nitrile oxides
can also be used for the reaction with alkenes (Table 1, entry
9) and norbornenes (Table 1, entry 10). Here, nucleotides were
equipped with norbornenes or alkenes and were subsequently
used in the synthesis of oligonucleotides, and lastly reacted
with in situ formed nitrile oxides.92,93 In the study involving
alkene–nitrile oxide ligation, not only the alkene-functionality
but also alkyne-groups were introduced. It was shown that the
alkynes could first be labelled using CuAAC whereupon the
alkenes were labelled with nitrile oxides.93
Most recently it was shown that nitrile oxides also react
with cyclooctynes (so-called SPANOC, Table 1, entry 11).88,94
This reaction showed almost a 100-fold rate increase compared
to SPAAC, and was used for the modification of oligosacchar-
ides,94 small peptides,88 and DNA immobilised in solid
phase.95
A disadvantage of using nitrile oxides is that their reactivity
also makes them unstable, and in situ preparation directly fol-
lowed by cycloaddition is required. Nitrones, on the other
hand, appear to be more stable and still react in a fast and
selective manner with cyclooctynes in a strain-promoted
alkyne nitrone cycloaddition (SPANC, Table 1, entry 12).89,96
For this reaction, the reactivity largely depended on the
nature of the nitrone, with rate constants ranging within 3
orders of magnitude. Cyclic nitrones were found to be most
eﬃcient.97,98 SPANC has found multiple applications in cancer
research. Pezacki et al. targeted human breast cancer cells with
epidermal growth factor (EGF), which was functionalised with
cyclic nitrones using NHS-based chemistry. The cells could
subsequently be labelled using a biotin-functionalised cyclo-
octyne, and imaged with a fluorescent streptavidin.97 Prosperi
and co-workers showed that SPANC could be used for the
attachment of nitrone-functionalised antibodies to magnetic
nanoparticles. After modification, these particles still showed
aﬃnity for the tumour marker HER2.99
Raines et al. recently published that diazo compounds can
also react in a 1,3-dipolar cycloaddition with a dibenzocyclooc-
tyne (DIBONE,100 Table 1, entry 13).101 The diazo compounds
were prepared by treating an azide with a phosphinoester.
Depending on the electron delocalisation of the dipole, the
reaction rate varied from 10-fold higher compared to the
corresponding azide for a highly delocalised diazo compound,
to over 10-fold lower for an electron-deficient diazo
compound.
2.4 Ligations with tetrazines
An interesting alternative to the 1,3-dipolar cycloadditions
described above is tetrazine-based ligations. These reactions
are inverse electron demand Diels–Alder reactions, followed by
a retro-Diels–Alder reaction, eliminating N2, shown in
Scheme 3. As for the reaction between cyclooctynes and azides,
the literature already shows extensive investigations into
cycloadditions between tetrazines and strained alkenes and
alkynes. In these reports, the eﬀect of ring strain, double bond
stereochemistry, and the influence of heteroatoms in rings on
the reaction rate have already been described.102,103 In spite of
this research, only in 2008 Hilderbrand and Fox almost simul-
taneously published the modification of proteins and cell sur-
faces using tetrazine-based ligations (Scheme 3).
Hilderbrand and co-workers demonstrated that norbor-
nenes react with tetrazines (Table 1, entry 15) with similar
rates (1.6–1.9 M−1 s−1)104 as the fastest SPAAC reactions
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(1.5 M−1 s−1 being the fastest rate reported).68 This reaction
was successfully applied in the labelling of tumour cells.
Fox et al. showed that tetrazines react extremely fast with
diﬀerent trans-cyclooctenes (Table 1, entry 14, rate constants of
1–22 × 103 M−1 s−1) compared to the SPAAC reaction.105,106
This reaction has, for example, been applied for the intracellu-
lar labelling of the anti-cancer drug taxol, and the preparation
of 18F-PET tracers.107 Interestingly, the incredible speed of
these reactions also allowed for pretargeting. It was shown that
sequential incubation of tumour cells with trans-cyclooctene-
labelled antibodies, followed by tetrazine-functionalised nano-
particles, led to a higher degree of labelling as for the full anti-
body-nanoparticle construct.108 Rossin et al. showed the
potential of this reaction for in vivo labelling. They pretargeted
tumors in mice with trans-cyclooctene functionalised anti-
bodies, and then separately injected an In3+-labelled tetrazine
to show successful tumour labelling.5 An advantage of this last
method is that the small tetrazine is cleared within several
hours from the blood, whereas the full antibody takes over
24 hours before clearance. This significantly decreases the
time between injection and imaging, which especially might
turn out to be useful for fast decaying radioisotopes. A similar
observation was made by Brindle et al. who could increase the
signal-to-noise ratio by using the TCO-tetrazine cycloaddition
instead of SPAAC for label introduction.87
In addition, it was recently shown that tetrazines react with
cyclooctynes (Table 1, entry 16),109 which was applied for
protein modification.110,111 Interestingly, monosubstituted
tetrazines do react at a much lower rate with dibenzocyclo-
octynes, compared to cyclooctynes. Disubstituted tetrazines
give no cycloaddition product at all with dibenzocyclooctynes.
Another interesting, newly arisen probe for tetrazine-based lig-
ation is the cyclopropene (Table 1, entry 17),113 which already
found applications in cell surface labelling.113–115 Most
recently, it was also shown that tetrazines can react with
alkenes (Table 1, entry 18)116 and isonitriles (Table 1, entry
19),117 and both reactions were successfully used in cell
surface labelling.
Notably, not all tetrazines are stable in serum, some degrad-
ing in water and/or by the addition of thiols. Hilderbrand et al.
prepared a wide range of tetrazines and tested them for reacti-
vity and serum stability.118 In addition, they prepared tetrazines
which become fluorescent upon reaction.119
2.5 Ligations with tetrazoles
Tetrazoles themselves are no reactive partners in cycloaddition
reactions. However, it was shown that upon irradiation with
UV-light, nitrogen is excluded and a nitrile imine 1,3-dipole is
formed.120 In the absence of a reactive partner for this dipole,
formation of a water-adduct was observed; however, in the
presence of acrylamides (Table 1, entry 20),121 norbornenes
(Table 1, entry 21)122 and cyclopropenes (Table 1, entry 22)123
the nitrile imines rapidly form pyrazolines, as shown in
Scheme 4. The reactivity of the 1,3-dipole depends on the sub-
stituents on the nitrile imine.124 It was shown that this reac-
tion can be used for the labelling of proteins, also inside
cells,125 for example towards studying perturbing protein local-
isation.126 Notably, the reaction only occurs upon UV
irradiation, thereby allowing temporal and spatial control over
the ligation.
2.6 Other bioorthogonal ligation reactions
In the last couple of years, also metal-catalysed reactions have
found applications in the modification of proteins. For
example, Davis et al. showed that cross-metathesis can be used
for protein modification (Table 1, entry 24). For this modifi-
cation, an S-allyl cysteine or Se-allyl functionality is required
which reacts with allyl-functionalized saccharides or small
ethylene glycol tails.127,128 It was also demonstrated that the
Suzuki–Miyaura coupling (Table 1, entry 26)129 and the Sono-
gashira reaction (Table 1, entry 25)130 can be applied for the
labelling of proteins.
A completely new bioorthogonal reaction was recently deve-
loped by Sletten and Bertozzi, who sought to develop a new
reaction, orthogonal to the known cohort of bioconjuga-
tions.131 They encountered that quadrocyclanes have a large
ring strain which makes them likely to react fast with a suit-
able reaction partner, which was found in the Ni(dithiolene)2
complex (Table 1, entry 23). The obtained cycloaddition
product however slowly decomposed, unless a metal-chelator
was added. This reaction could be used for protein modifi-
cation and proved orthogonal to SPAAC and oxime-formation.
3. Orthogonality
In addition to the search for bioorthogonal reactions, interest
has also grown in bioorthogonal reactions which are also
mutually orthogonal. The latter class of reactions can be useful
in, for example, dual labelling or for the introduction of mul-
tiple functional handles.
The abovementioned reaction between a quadrocyclane and
an Ni(dithiolene)2 complex was specifically developed for this
Scheme 3 Inverse-electron demand Diels–Alder reaction, followed by a retro-
Diels–Alder reaction.
Scheme 4 Formation of nitrile imines from tetrazoles, followed by a 1,3-
dipolar cycloaddition with alkenes.
Organic & Biomolecular Chemistry Perspective
This journal is © The Royal Society of Chemistry 2013 Org. Biomol. Chem., 2013, 00, 1–17 | 11
1
5
10
15
20
25
30
35
40
45
50
55
1
5
10
15
20
25
30
35
40
45
50
55
purpose, and was found to be orthogonal to SPAAC and oxime
ligation.131 However, also other bioorthogonal reactions are
found to be mutually orthogonal. In Table 3 an overview is pro-
vided of the bioorthogonal reactions depicted in Table 1 and
their compatibility in reactivity when performed simul-
taneously. Apart from adding all reagents at once in one pot,
reactions can also be performed consecutively. Performing
bioorthogonal reactions in this manner, possibly with an inter-
mediate purification step, allows for significantly more
bioorthogonal reactions to be used on the same biological
system. An overview of these possibilities is depicted in
Table 4. Obviously, reactions using one or more identical
reagents cannot be used simultaneously. Besides, reactions
requiring either a catalyst or activation by UV-light
form orthogonal pairs when performed consecutively, as long
as both the reactions do not require the same type of
activation.
Entries 1–3, which involve diﬀerent reactions with alde-
hydes and/or ketones, are probably orthogonal towards all
other bioorthogonal reactions. Nonetheless, one might argue
the real bioorthogonality of the carbonyl moiety, especially in
biological media containing high concentrations of amines.
In the case of the azide moiety (entries 4–7) orthogonality is
harder to achieve. The Staudinger-type reactions (entries 5 and
6) involve such azide-specific chemistry that these are likely
orthogonal to all reactions not involving azides or azide-reac-
tive groups.
However, for entries 4 and 7, due to the reactivity of the
azide towards terminal alkynes (when catalysed by Cu(I) or
Ru(II)) and (dibenzo)cyclooctynes, in combination with the
reactivity of other functional handles (nitrile-oxides, nitrones,
diazo compounds, tetrazines, and tetrazoles) towards these
moieties, only a few of these reactions are likely to be mutually
orthogonal. Nonetheless, there are some examples of using
multiple bioorthogonal reactions in one pot, of which one
involved an azide. Hilderbrand et al. demonstrated that SPAAC
with dibenzocyclooctynes and tetrazines with TCOs can be
used in a single pot.112 No cross reaction between tetrazines
and dibenzocyclooctynes was observed, and the rate constant
of TCOs with azides was almost three orders of magnitude
slower than SPAAC. To demonstrate the orthogonality, two
diﬀerent cell types were equipped with either a dibenzo-
cyclooctyne or a TCO and subsequently mixed, and selectively
labelled with two diﬀerent dyes. It was also demonstrated that
cells grown with both azide- and cyclopropene-containing
sialic acids could be labelled orthogonally.114 Most recently, it
was shown that alkene-containing Ac4ManNAc and Ac4GalNAz
can be incorporated in the same cell and subsequently
labelled selectively using a tetrazine-dye for the alkene-sugar
and a dibenzocyclooctyne for the azido-sugar.116
The lack of reactivity between tetrazine and dibenzoaza-
cyclooctyne compared to tetrazine and cyclooctyne and the low
reactivity between azide and TCO compared to tetrazine and
TCO has been explored by Houk et al.132 Based on DFT
Table 3 Overview of mutual orthogonality of bioorthogonal reactions when performed in a “one-pot procedure”. means the reactions are orthogonal,
means they are not, implies the reactions are likely to be orthogonal, and implies the reactions are unlikely to be orthogonal.
a If no catalyst is used to control the regiochemistry of nitrile-oxide alkyne cycloaddition. bOnly for DBCO.
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calculations, they reasoned that the activation energy for the
reaction between TCO and azide is significantly higher than
that for the inverse electron demand Diels–Alder reaction,
causing high selectivity of TCO for the tetrazine. The low reac-
tivity of dibenzocyclooctynes (as opposed to cyclooctynes) with
tetrazines is caused by steric eﬀects, resulting in a high distor-
tion energy.
The orthogonality of these two reactions was also used by
Brindle et al. who demonstrated that a double-click protocol
can be performed for tumour-labelling in live mice.87 Tumour
cells were grown in mice in the presence of Ac4GalNAz, thereby
equipping the tumour cells with azides in vivo. Hereupon, the
azides were reacted with a bifunctional probe, containing a
dibenzocyclooctyne and a TCO. The azides now selectively
reacted with the dibenzocyclooctyne, and upon clearance of
the bifunctional probe, the TCO could be used for an inverse
electron demand Diels–Alder reaction. An advantage of this
approach compared to one step labelling with an imaging
probe containing dibenzocyclooctyne is that due to its high
reaction kinetics, the tetrazine probe needs to be administered
in a much lower concentration compared to the dibenzo-
cyclooctyne, thereby increasing the signal-to-noise ratio.
However, one might argue that a one-step approach involving
one fast ligation method would be more straightforward.
It was also demonstrated by Jäschke et al. that the CuAAC and
TCO-tetrazine ligation can be used simultaneously, to achieve
dual labelling of DNA.133
Nitrile-oxides (entries 8–11) react with similar moieties as
tetrazoles and tetrazines, making it hard to find orthogonal
pairs. Nonetheless, it was shown that dual-labelling of DNA
can be achieved by performing CuAAC, followed by a cyclo-
addition between a nitrile-oxide and an alkene.93
Reactivity of nitrones and diazo compounds (entries 12 and
13) with other reactive groups than cyclooctynes has not been
widely studied and therefore it is hard to estimate the compat-
ibility with other reactions. However, as the reactivity of
nitrones and diazo compounds with strained alkynes is com-
parable to or higher than the reactivity of nitrile-oxides with
strained alkynes, the reactivity of nitrones and diazo com-
pounds likely resembles the reactivity of nitrile-oxides.
Looking at the moieties that react in a rapid manner with
tetrazines (entries 14–19), orthogonality towards other reactive
groups is hard to achieve. As mentioned earlier, the only sur-
prising lack of reactivity is observed when mixing tetrazines
with dibenzocyclooctynes. Especially for the consecutive reac-
tions this opens up some possibilities for orthogonal reacti-
vity.112 Consecutive reactions of azide-related chemistry
followed by most tetrazine-involving cycloadditions (except
Table 4 Overview of mutual orthogonality of bioorthogonal reactions when performed in a consecutive manner. means the reactions are orthogonal,
means they are not, implies the reactions are likely to be orthogonal, implies the reactions are unlikely to be orthogonal, means the reaction corres-
ponding to the lowest entry number is performed ﬁrst, and means the reaction corresponding to the highest entry number is performed ﬁrst.
aOnly if no reaction of nitrone/diazo compound/tetrazine with terminal alkyne. b If no catalyst is used to control regiochemistry of nitrile-oxide
alkyne cycloaddition. c S goes anyway, T probably, assuming that the reaction between azide and norbornene is significantly slower. d Both ways
for dibenzocyclooctynes, only T for cyclooctynes. e Also S in the case of DBCOs. fOnly for DBCO.
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entry 16) can be performed, due to the low reactivity of azides
with TCOs,134 norbornenes, cyclopropenones,114 and
alkenes.116
For tetrazoles (entries 20–22), cycloaddition has been
observed with similar reactive groups as for tetrazines and
nitrile-oxides; however, as mentioned earlier, no reactivity of
alkenes, norbornenes, and cyclopropenes has been observed
for azides, allowing for some orthogonality in these cases. For
consecutive reactions, the big advantage of tetrazoles is that
they require activation. Therefore, the first reaction (e.g. a tetra-
zine with an alkene) can be performed whereupon the tetra-
zole is activated and reacted with another functional handle.
This only works under the assumption that all tetrazines have
reacted and that the first reagent can be washed away.
The quadrocyclane (entry 23), which was developed by
Bertozzi et al. keeping orthogonality in mind, was shown to be
orthogonal to SPAAC and the reaction between an aldehyde
and an alkoxyamine.131 Although further research on ortho-
gonality has not been performed, likely due to a lack of double
bonds, the reaction is orthogonal to the full cohort of reactions
described in Table 1.
The last category is formed by the metal-catalysed reactions
(entries 24–26). Although the cross-reactivity of alkenes and
alkynes with several functional handles excludes some reac-
tions to be performed simultaneously, the catalyst require-
ments do allow for performing consecutive reactions.
4. Conclusions and outlook
This literature overview makes clear that the field of bioortho-
gonal ligation reactions is still expanding. In recent years,
various highly promising reactions have been developed, and a
wide range of applications have been reported.
For reactions to be applicable in biological systems, they
need to fulfil several requirements. Hydrophilicity, reaction
kinetics, and selectivity are probably the most important
factors for a successful ligation. With these requirements in
mind, the tetrazine-based ligations with trans-cyclooctenes or
cyclopropenes seem the most suitable reactions. These liga-
tions show amazing rate constants (103–104 M−1 s−1) and high
selectivity. However, as the tetrazine is a relatively large residue
and hard to selectively introduce compared to the azide,
protein functions are more likely to be disturbed. Azides, on
the other hand, are easily introducible small residues, forming
a peptide bond isostere upon cycloaddition.
Overall, it can be concluded that for each application a
diﬀerent ligation might be preferred. For example, bioorthogo-
nal ligation is not at all required if the aim is to prepare a
labelled protein irrespective of the modification site or
number of labels introduced.3 With that aim in mind probably
lysine or cysteine modification is the easiest choice.
On the other hand, introduction of azides into multiple
proteins can relatively easily be achieved in vitro and in vivo.
Subsequent labelling with CuAAC or SPAAC allows for proteo-
mics and in vivo imaging of glycan synthesis,4 respectively.
Tetrazine-based ligations are most suitable when a fast reac-
tion is required, e.g. for in vivo radiolabelling5 or in single
protein labelling.110 Nonetheless, there is still room for
improvement. One of the challenges in the coming years is to
develop a fluorogenic probe which after reaction shows an
emission–excitation pattern that is more suitable for biological
research than coumarin-based dyes, as for FI-DIBO79 and
CoumBARAC.78 Very recently, two fluorogenic probes, i.e. an
azide77 and a tetrazine,135 were reported which display more
preferable excitation wavelengths (around 500 m) upon cyclo-
addition. Also, the development of tunable probes is likely to
prove valuable in biological research, allowing for spatial and
temporal control. The tetrazole-based ligation121 and cyclopro-
pene-protected dibenzocyclooctyne64 are already examples in
this direction. However, both require irradiation with UV-light,
which makes them less suitable for biological studies. Poss-
ibly, diﬀerent types of probes can be developed which become
reactive upon irradiation with for example α-particles, X-rays,
or by drug interaction. Lastly, the fastest bioorthogonal liga-
tions involve relatively large reactive groups. The larger the
molecules, the bigger the chances that the biological pro-
cesses, epitope aﬃnity, or enzyme functioning are influenced.
To circumvent this, a challenge lies in the development of two
small reactive partners which react in a fast and selective
manner with each other. A promising advance in this field was
recently made by the development of a tetrazine-cyclopro-
pene113 and tetrazole-cyclopropene123 cycloaddition.
As bioconjugation has proven its value more and more in
the last decade, it is likely that additional research areas will
pick up on bioorthogonal ligation reactions. Currently, mainly
biology-oriented chemists and macromolecular chemists have
discovered this chemistry. However, with a growing number of
reagents, e.g. cyclooctynes and tetrazines, becoming commer-
cially available, also biologists will have access to these types
of chemistries and will be able to apply it in their respective
research fields.
In addition, interest in the development of new bioorthogo-
nal ligation strategies certainly has not decreased over the
years; instead the opposite appears to be true. Reactivity which
can be achieved with SPAAC seems to have reached its limit;
however, other, new reactions with superior kinetics have been
developed and have not been optimized yet. Therefore, one
may expect that in the years to come, even better and more
selective ligation strategies will be discovered.
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